Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
May 09, 2024 09:00 ET
|
Curia Global, Inc.
The symposium, Unlocking High-Throughput Biology in Drug Discovery, will take place on May 31 in Seattle and feature industry-leading scientists.
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
May 09, 2024 07:30 ET
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Avid Bioservices to Participate at Upcoming Investor Conferences
May 07, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly and Company, Merck Sharp & Dohme LLC, T
May 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
April 24, 2024 17:25 ET
|
Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Biologics Market Size Expected to Reach USD 845.78 Billion by 2033
March 12, 2024 11:20 ET
|
Precedence Research
Ottawa, March 12, 2024 (GLOBE NEWSWIRE) -- The global biologics market size was valued at USD 419.07 billion in 2023 and is projected to surpass around USD 698.17 billion by 2031, a study published...
Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding
March 11, 2024 08:00 ET
|
Qu Biologics, Inc.
BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
March 06, 2024 23:58 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
March 06, 2024 16:32 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...